NutraLife BioSciences, Inc.
NLBS
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 15.82% | -6.55% | -52.44% | -50.09% | -51.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.82% | -6.55% | -52.44% | -50.09% | -51.43% |
| Cost of Revenue | 57.44% | 20.79% | -1.04% | -27.19% | -62.73% |
| Gross Profit | -46.58% | -73.18% | -99.76% | -83.60% | -10.80% |
| SG&A Expenses | -52.58% | -49.87% | -49.01% | 78.90% | 108.95% |
| Depreciation & Amortization | 5,430.23% | 3,240.63% | 8,957.89% | 114,500.00% | -146.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.25% | -39.93% | -40.60% | 57.93% | 61.51% |
| Operating Income | 47.91% | 44.50% | 37.13% | -126.69% | -121.72% |
| Income Before Tax | 17.19% | 23.90% | -22.92% | -134.96% | -90.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.19% | 23.90% | -22.92% | -134.96% | -90.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.19% | 23.90% | -22.92% | -134.96% | -90.13% |
| EBIT | 47.91% | 44.50% | 37.13% | -126.69% | -121.72% |
| EBITDA | 51.55% | 47.49% | 39.39% | -136.09% | -130.54% |
| EPS Basic | 24.27% | 30.83% | -12.72% | -108.59% | -30.21% |
| Normalized Basic EPS | 23.36% | 29.34% | -12.37% | -125.20% | -35.56% |
| EPS Diluted | 24.27% | 30.83% | -12.72% | -108.59% | -30.21% |
| Normalized Diluted EPS | 23.36% | 29.34% | -12.37% | -125.20% | -35.56% |
| Average Basic Shares Outstanding | 9.08% | 11.49% | 12.06% | 12.93% | 23.54% |
| Average Diluted Shares Outstanding | 9.08% | 11.49% | 12.06% | 12.93% | 23.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
